Advertisement

How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?

      Highlights

      • Few FH patients achieve LDL targets despite high-intensity lipid-lowering therapy.
      • Despite statin therapy, they are high cardiovascular risk patients.
      • PCSK9 inhibitors increase significantly the number of patients achieving LDL targets.
      • Only 17% FH are eligible for PCSK9 inhibitors according European guidelines.
      • Wider access of FH patients to PCSK9 inhibitor therapy is warranted.

      Abstract

      Background and aims

      Familial hypercholesterolemia (FH) is a high cardiovascular risk condition. Less than 20% of patients achieve the LDL targets. Although PCSK9 inhibitors improve control and reduce cardiovascular events, official recommendations for their use are restrictive. We aim to assess the number of FH patients suitable for PCSK9 inhibition according to the European guidelines.

      Methods

      A total of 2685 FH patients, with a minimum follow-up of 6 months, included in the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, were sorted according to the intensity of their lipid-lowering therapy (LLT) and LDL cholesterol levels achieved. The number of patients who met the recommendations for PCSK9 inhibition treatment according to the European Atherosclerosis Society (ESC/EAS), Spanish Arteriosclerosis Society and the European Medicines Agency was calculated.

      Results

      In total, 1573 patients were on high-intensity LLT; 607 were on moderate-intensity statins; 82 were on low-intensity LLT, and 423 were neither on statins nor on ezetimibe in the last visit registered. The mean LDL reduction among those on high-intensity LLT was 54%. Ninety-one percent of patients on high-intensity LLT had an LDL below 5.2 mmol/L, 53% below 3.4 mmol/L, and 23% below 2.6 mmol/L. Only 12% of FH patients with cardiovascular disease achieved 1.8 mmol/L. Despite this, only 17% of patients qualified for PCSK9 inhibition according to ESC/EAS guidelines.

      Conclusions

      For patients with a condition that exposes them to high cardiovascular risk and who have extreme difficulties in achieving LDL targets, wider access to PCSK9 inhibitor therapy is warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wald D.S.
        • Bestwick J.P.
        • Morris J.K.
        • Whyte K.
        • Jenkins L.
        • Wald N.J.
        Child-parent familial hypercholesterolemia screening in primary care.
        N. Engl. J. Med. 2016; 375: 1628-1637https://doi.org/10.1056/NEJMoa1602777
        • De Ferranti S.D.
        • Rodday A.M.
        • Mendelson M.M.
        • Wong J.B.
        • Leslie L.K.
        • et al.
        Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES).
        Circulation. 2016; 133: 1067-1072https://doi.org/10.1161/CIRCULATIONAHA.115.018791
        • De Backer G.
        • Besseling J.
        • Chapman J.
        • Hovingh G.K.
        • Kastelein J.J.P.
        • et al.
        Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology.
        Atherosclerosis. 2015; 241: 169-175https://doi.org/10.1016/j.atherosclerosis.2015.04.809
        • Wong B.
        • Kruse G.
        • Kutikova L.
        • Ray K.K.
        • Mata P.
        • Bruckert E.
        Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature.
        Clin. Ther. 2016; 38: 1696-1709https://doi.org/10.1016/j.clinthera.2016.05.006
        • Béliard S.
        • Millier A.
        • Carreau V.
        • Carrié A.
        • Moulin P.
        • et al.
        The very high cardiovascular risk in heterozygous familial hypercholesterolemia: analysis of 734 French patients.
        J. Clin. Lipidol. 2016; : 1129-1136https://doi.org/10.1016/j.jacl.2016.06.007
        • Piepoli M.F.
        • Hoes A.W.
        • Agewall S.
        • Albus C.
        • Brotons C.
        • et al.
        European Guidelines on cardiovascular disease prevention in clinical practice.
        Eur. Heart J. 2016; 37: 2315-2381https://doi.org/10.1093/eurheartj/ehw106
        • Catapano A.L.
        • Graham I.
        • De Backer G.
        • Wiklund O.
        • Chapman M.J.
        • et al.
        ESC/EAS guidelines for the management of dyslipidaemias.
        Eur. Heart J. 2016; 37: 2999-30581https://doi.org/10.1093/eurheartj/ehw272
        • Lloyd-Jones D.M.
        • Morris P.B.
        • Ballantyne C.M.
        • Birtcher K.K.
        • Daly D.D.
        • et al.
        ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk a report of the American College of Cardiology task force on clinical expert conse.
        J. Am. Coll. Cardiol. 2016; 68: 92-125https://doi.org/10.1016/j.jacc.2016.03.519
        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • Ginsberg H.N.
        • Masana L.
        • et al.
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
        Eur. Heart J. 2013; 34: 3478-3490ahttps://doi.org/10.1093/eurheartj/eht273
        • Krogh H.W.
        • Mundal L.
        • Holven K.B.
        • Retterstøl K.
        Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death.
        Eur. Heart J. 2015; : 1398-1405https://doi.org/10.1093/eurheartj/ehv602
        • Perak A.M.
        • Ning H.
        • De Ferranti S.D.
        • Gooding H.C.
        • Wilkins J.T.
        • Lloyd-Jones D.M.
        Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype.
        Circulation. 2016; 134: 9-19https://doi.org/10.1161/CIRCULATIONAHA.116.022335
        • De Isla L.P.
        • Alonso R.
        • Mata N.
        • Saltijeral A.
        • Muñiz O.
        • et al.
        Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study).
        Arterioscler. Thromb. Vasc. Biol. 2016; 36: 2004-2010https://doi.org/10.1161/ATVBAHA.116.307514
        • García-Gil M.
        • Blanch J.
        • Comas-Cufí M.
        • Daunis-I-Estadella J.
        • Bolíbar B.
        • et al.
        Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: a retrospective study of primary care electronic medical records.
        J. Clin. Lipidol. 2016; 10: 134-142https://doi.org/10.1016/j.jacl.2015.10.007
        • Ridker P.M.
        • Mora S.
        • Rose L.
        Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.
        Eur. Heart J. 2016; 37: 1373-1379https://doi.org/10.1093/eurheartj/ehw046
        • Perez De Isla L.
        • Alonso R.
        • Watts G.F.
        • Mata N.
        • Saltijeral Cerezo A.
        • et al.
        Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up.
        J. Am. Coll. Cardiol. 2016; 67: 1278-1285https://doi.org/10.1016/j.jacc.2016.01.008
        • Masana L.
        • Lennep J.R.V.
        Dose wisely! How lipid-lowering undertreatment can lead to overtreatment.
        Atherosclerosis. 2016; 255https://doi.org/10.1016/j.atherosclerosis.2016.10.014
        • Gitt A.K.
        • Lautsch D.
        • Ferrieres J.
        • Kastelein J.
        • Drexel H.
        • et al.
        Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
        Atherosclerosis. 2016; 255: 200-209https://doi.org/10.1016/j.atherosclerosis.2016.09.004
        • Langsted A.
        • Freiberg J.J.
        • Nordestgaard B.G.
        Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004–2014.
        Atherosclerosis. 2017; 257: 9-15https://doi.org/10.1016/j.atherosclerosis.2016.11.025
        • Gouni-Berthold I.
        • Descamps O.S.
        • Fraass U.
        • Hartfield E.
        • Allcott K.
        • et al.
        Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
        Br. J. Clin. Pharmacol. 2016; 82: 1412-1443https://doi.org/10.1111/bcp.13066
        • Nicholls M.S.J.
        • Puri R.
        • Anderson T.
        • Ballantyne C.M.
        • Cho L.
        • et al.
        Effect of evolocumab on progression of coronary disease in statin-treated PatientsThe GLAGOV randomized clinical trial.
        JAMA. 2016; : 1-12https://doi.org/10.1001/jama.2016.16951
        • Lipinski M.J.
        • Benedetto U.
        • Escarcega R.O.
        • Biondi-Zoccai G.
        • Lhermusier T.
        • et al.
        The impact of proprotein convertase subtilisin- kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
        Eur. Heart J. 2016; 37: 536-545https://doi.org/10.1093/eurheartj/ehv563
      1. Assessment Report. European Medicines Agency. EMA/CHMP/392430/2015.

        • Landmesser U.
        • Chapman M.J.
        • Farnier M.
        • Gencer B.
        • Gielen S.
        • et al.
        European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.
        Eur. Heart J. 2016; (ehw480)https://doi.org/10.1093/eurheartj/ehw480
      2. L. Masana, J.F. Ascaso, F. Civeira, J. Pedro-Botet, P. Valdivielso, et al. Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9. Clin. Invest. Arterioscler. 28 (n.d.) 164–165. doi:10.1016/j.arteri.2016.02.001.

        • Pérez de Isla L.
        • Alonso R.
        • Mata N.
        • Fernández-Pérez C.
        • Muñiz O.
        • et al.
        Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry.
        Circulation. 2017; (CIRCULATIONAHA.116.024541)https://doi.org/10.1161/CIRCULATIONAHA.116.024541
        • Raal F.J.
        • Stein E.A.
        • Dufour R.
        • Turner T.
        • Civeira F.
        • et al.
        PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2015; 385: 331-340https://doi.org/10.1016/S0140-6736(14)61399-4
        • Kastelein J.J.P.
        • Ginsberg H.N.
        • Langslet G.
        • Kees Hovingh G.
        • Ceska R.
        • et al.
        ODYSSEY FH i and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
        Eur. Heart J. 2015; 36: 2996-3003https://doi.org/10.1093/eurheartj/ehv370
        • Kuder J.F.
        • Wang H.
        • Liu T.
        • Wasserman S.M.
        • Sever P.S.
        • et al.
        Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
        2017: 1-10https://doi.org/10.1056/NEJMoa1615664
        • Ridker P.M.
        • Revkin J.
        • Amarenco P.
        • Brunell R.
        • Curto M.
        • et al.
        SPIRE cardiovascular outcome investigators, cardiovascular efficacy and safety of bococizumab in high-risk patients.
        N. Engl. J. Med. 2017; 376: 1527-1539https://doi.org/10.1056/NEJMoa1701488
        • Villa G.
        • Lothgren M.
        • Kutikova L.
        • Lindgren P.
        • Gandra S.R.
        • et al.
        Cost-Effectiveness of evolocumab in patients with high cardiovascular risk in Spain.
        Clin. Ther. 2017; : 1-19https://doi.org/10.1016/j.clinthera.2017.02.011
        • Kazi D.S.
        • Moran A.E.
        • Coxson P.G.
        • Penko J.
        • Ollendorf D.A.
        • et al.
        Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.
        JAMA. 2016; 316: 743https://doi.org/10.1001/jama.2016.11004
        • Robinson J.G.
        • Huijgen R.
        • Ray K.
        • Persons J.
        • Kastelein J.J.P.
        • Pencina M.J.
        Determining when to add nonstatin therapy: a quantitative approach.
        J. Am. Coll. Cardiol. 2016; 68: 2412-2421https://doi.org/10.1016/j.jacc.2016.09.928